Serial entrepreneur and marketing strategist in healthcare communications, consumer insights, and franchise development. Founded a medical patient education firm adopted by 3,000+ hospitals and viewed by 1M+ patients annually. At Comprehensive Loyalty, oversaw 400+ predictive site studies and 200,000+ consumer surveys, and supported 50+ companies. CEO since 2015; named inventor on 8 U.S. patents.

Electrical engineer with 40+ years leading high-reliability systems in defense and medical technology. Former Engineering Manager at Northrop Grumman overseeing 30 engineers. Now directs architecture, hardware development, and system innovation for the LB10000 Adaptive Tumor Treating Field platform.

Physicist and former Director of Science at Novocure (NASDAQ: NVCR), where he built and led a physics and algorithms team focused on Tumor Treating Fields. Co-inventor on 30+ patents and author of 20+ peer-reviewed publications. At LifeBridge, leads field modeling, dose optimization, in-vivo study design, and scientific strategy for Adaptive Tumor Treating Fields.

Board-certified oncologist and former 10-year Director of Clinical Research at AdventHealth Cancer Institute. Principal Investigator on 100+ early- and late-stage cancer clinical trials, with publications in Journal of Clinical Oncology and Annals of Oncology. Provides clinical oversight and medical strategy for LifeBridge’s Adaptive Tumor Treating Fields program.

Technologist and engineer with nearly 30 years in commercial and defense systems, including roles at Lockheed, Northrop Grumman, and Martin Marietta. Recipient of a Technical Emmy for high-definition imaging systems. Leads embedded software, simulations, and product development for the LB10000 Adaptive Tumor Treating Fields platform.

Medical device regulatory executive with 30+ years’ experience, including senior roles at Medtronic and Boston Scientific. Directed 50+ successful device clearances. Leads FDA engagement, IDE/PMA strategy, and regulatory compliance for LifeBridge. Formerly led the Regulatory Science program at the University of St. Thomas.

Medical device executive with 20+ years’ experience in CEO, CFO, and COO roles across early- and growth-stage companies. Led a device startup from early commercialization through a successful strategic exit and held executive roles at Advanced Circulatory Systems (acquired by ZOLL). Advises early-stage medtech companies and angel investor networks.

Biotechnology entrepreneur and former CEO of StemoniX, which merged with public company Vyant Bio in 2021. Background spans life sciences and enterprise technology commercialization, including leadership roles at Seagate, Samsung partnerships, and Dell enterprise systems. Brings public company and exit experience to LifeBridge’s board.

Investment executive with 40+ years in public and private markets. Spent over 30 years at Merrill Lynch and Morgan Stanley managing a $300M equity and debt portfolio. Has invested in and exited multiple private companies across technology and healthcare sectors. Provides capital markets oversight and financial governance.